Related Experiment Video

Updated: Aug 6, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Basic and Translational Research Advances in NSCLC

Rajal Sharma1,2, Katerina Politi1,2,3

  • 1Yale Cancer Center.

Cancer Journal (Sudbury, Mass.)
|July 24, 2026
PubMed

Insights

Lung cancer treatments have improved, but cures for metastatic disease are still needed. Understanding resistance, heterogeneity, and the tumor microenvironment is key for future lung cancer therapies.

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Medicine

Background:

  • Lung cancer treatments have advanced, improving survival over the past two decades.
  • Despite progress, lung cancer mortality remains high, and cures for metastatic disease are elusive.

Purpose of the Study:

  • To outline recent advances in lung cancer biology.
  • To identify key areas for future therapeutic development in lung cancer.

Main Methods:

  • Review of recent scientific literature on lung cancer biology.
  • Focus on resistance mechanisms, tumor heterogeneity, plasticity, minimal residual disease, and the tumor microenvironment.

Main Results:

  • Advances in understanding lung cancer biology are providing new therapeutic targets.
  • Key areas influencing tumor biology include resistance mechanisms, heterogeneity, plasticity, minimal residual disease, and the tumor microenvironment.

Conclusions:

  • A comprehensive understanding of these biological factors is essential for developing effective future lung cancer therapies.
  • Improving the care of lung cancer patients requires continued research into these critical areas.
Keywords:
NSCLCimmunotherapyintratumor heterogeneitylineage plasticityresistancetumor microenvironment

More Related Videos

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma07:59

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma

Published on: April 3, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...